{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:49:06Z","timestamp":1771656546181,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970283"],"award-info":[{"award-number":["81970283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000463"],"award-info":[{"award-number":["82000463"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270398"],"award-info":[{"award-number":["82270398"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bcp.2023.115443","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T01:39:52Z","timestamp":1675042792000},"page":"115443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action"],"prefix":"10.1016","volume":"209","author":[{"given":"He-qiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-le","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-long","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang-si","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang-bin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-long","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-da","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-jun","family":"Jie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115443_b0005","doi-asserted-by":"crossref","unstructured":"M.F.I. Leong Bin Abdullah, D. Singh, The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Korth.): A Comprehensive Review, Frontiers In Pharmacology 12 (2021) 726003. doi.org\/10.3389\/fphar.2021.726003.","DOI":"10.3389\/fphar.2021.726003"},{"key":"10.1016\/j.bcp.2023.115443_b0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fcvm.2018.00024","article-title":"Management of Chemotherapy-Induced Left Ventricular Dysfunction and Heart Failure in Patients With Cancer While Undergoing Cancer Treatment: The MD Anderson Practice","volume":"5","author":"Fadol","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"issue":"7","key":"10.1016\/j.bcp.2023.115443_b0015","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacep.2016.05.007","article-title":"Discontinuation of Dofetilide From QT Prolongation and Ventricular Tachycardia in the Real World","volume":"2","author":"Anand","year":"2016","journal-title":"JACC Clin. Electrophysiol."},{"key":"10.1016\/j.bcp.2023.115443_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174441","article-title":"Mechanisms of gefitinib-induced QT prolongation","volume":"910","author":"Jie","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115443_b0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bph.13679","article-title":"Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells","volume":"174","author":"Jie","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115443_b0030","doi-asserted-by":"crossref","unstructured":"A.F.d. Deus, V.L.d. Silva, S.L.B. de Souza, G.A.F. Mota, P.G. Sant'Ana, D.F. Vileigas, et al., Myocardial Dysfunction after Severe Food Restriction Is Linked to Changes in the Calcium-Handling Properties in Rats, Nutrients 11(9) (2019). doi.org\/10.3390\/nu11091985.","DOI":"10.3390\/nu11091985"},{"issue":"6","key":"10.1016\/j.bcp.2023.115443_b0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/CIRCRESAHA.113.301651","article-title":"Mechanisms of altered Ca2+ handling in heart failure","volume":"113","author":"Luo","year":"2013","journal-title":"Circ. Res."},{"issue":"11","key":"10.1016\/j.bcp.2023.115443_b0040","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0960-894X(03)00286-5","article-title":"Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta","volume":"13","author":"Faul","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-5793(89)81494-2","article-title":"Potent selective inhibitors of protein kinase C","volume":"259","author":"Davis","year":"1989","journal-title":"FEBS Lett."},{"issue":"21","key":"10.1016\/j.bcp.2023.115443_b0050","doi-asserted-by":"crossref","first-page":"15847","DOI":"10.1016\/S0021-9258(18)82331-6","article-title":"Protein kinase C isotypes in human erythroleukemia (K562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation","volume":"268","author":"Murray","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bcp.2023.115443_b0055","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.jid.5700322","article-title":"The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway","volume":"126","author":"Querfeld","year":"2006","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.bcp.2023.115443_b0060","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/1535-7163.MCT-05-0465","article-title":"Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines","volume":"5","author":"Rizvi","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.bcp.2023.115443_b0065","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10495-015-1125-1","article-title":"The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line","volume":"20","author":"Hagiwara","year":"2015","journal-title":"Apoptosis"},{"issue":"3","key":"10.1016\/j.bcp.2023.115443_b0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0092-8674(88)80027-8","article-title":"Overproduction of protein kinase C causes disordered growth control in rat fibroblasts","volume":"52","author":"Housey","year":"1988","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2023.115443_b0075","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood-2006-08-042747","article-title":"Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)","volume":"109","author":"Podar","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bcp.2023.115443_b0080","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.bcp.2023.115443_b0085","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2005.05.3447","article-title":"Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer","volume":"24","author":"Carducci","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jcph.573","article-title":"Effects of enzastaurin and its metabolites on the QT interval in cancer patients","volume":"56","author":"Welch","year":"2016","journal-title":"J. Clin. Pharmacol."},{"issue":"15 Pt 1","key":"10.1016\/j.bcp.2023.115443_b0095","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1158\/1078-0432.CCR-06-2912","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer","volume":"13","author":"Rademaker-Lakhai","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.bcp.2023.115443_b0100","doi-asserted-by":"crossref","first-page":"18585","DOI":"10.18632\/oncotarget.7875","article-title":"A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.bcp.2023.115443_b0110","doi-asserted-by":"crossref","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s42826-021-00102-3","article-title":"A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human: extrapolation of experimental insights to clinic","volume":"37","author":"Joukar","year":"2021","journal-title":"Lab Anim Res"},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.phrs.2010.07.008","article-title":"The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation","volume":"62","author":"Liu","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2023.115443_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.phrs.2015.12.012","article-title":"SKF-96365 blocks human ether-\u00e0-go-go-related gene potassium channels stably expressed in HEK 293 cells","volume":"104","author":"Liu","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bcp.2023.115443_b0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Water","year":"1989","journal-title":"J. Pharmacol. Methods"},{"issue":"4","key":"10.1016\/j.bcp.2023.115443_b0135","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/sj.bjp.0706352","article-title":"Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation","volume":"146","author":"Takahara","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115443_b0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vascn.2015.05.007","article-title":"QT interval correction assessment in the anesthetized guinea pig","volume":"75","author":"Morissette","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.bcp.2023.115443_b0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1251\/bpo22","article-title":"Measurement of Cardiac Mechanical Function in Isolated Ventricular Myocytes from Rats and Mice by Computerized Video-Based Imaging","volume":"3","author":"Ren","year":"2001","journal-title":"Biol. Proced. Online"},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2796.2005.01590.x","article-title":"In vitro and in vivo models for testing arrhythmogenesis in drugs","volume":"259","author":"Carlsson","year":"2006","journal-title":"J. Intern. Med."},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4161\/chan.2.2.6004","article-title":"Role of hERG potassium channel assays in drug development","volume":"2","author":"Priest","year":"2008","journal-title":"Channels (Austin)"},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development","volume":"25","author":"Recanatini","year":"2005","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.bcp.2023.115443_b0165","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2017.03.048","article-title":"Cryo-EM Structure of the Open Human Ether-a-go-go-Related K(+) Channel hERG","volume":"169","author":"Wang","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0170","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.105.098103","article-title":"Molecular determinants of cocaine block of human ether-\u00e1-go-go-related gene potassium channels","volume":"317","author":"Guo","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2023.115443_b0175","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1113\/jphysiol.1996.sp021410","article-title":"Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel","volume":"493","author":"Sch\u00f6nherr","year":"1996","journal-title":"J. Physiol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115443_b0180","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.RES.84.9.989","article-title":"Mechanism of block and identification of the verapamil binding domain to HERG potassium channels","volume":"84","author":"Zhang","year":"1999","journal-title":"Circ. Res."},{"issue":"6568","key":"10.1016\/j.bcp.2023.115443_b0185","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/379833a0","article-title":"The inward rectification mechanism of the HERG cardiac potassium channel","volume":"379","author":"Smith","year":"1996","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0190","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1085\/jgp.107.5.611","article-title":"Fast inactivation causes rectification of the IKr channel","volume":"107","author":"Spector","year":"1996","journal-title":"J. Gen. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0022-3565(25)38711-2","article-title":"K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes","volume":"269","author":"Slawsky","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0200","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/mol.60.2.244","article-title":"Open channel block of HERG K(+) channels by vesnarinone","volume":"60","author":"Kamiya","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/FJC.0b013e3181af6db3","article-title":"Pharmacologically induced long QT type 2 can be rescued by activation of IKs with benzodiazepine R-L3 in isolated guinea pig cardiomyocytes","volume":"54","author":"Nissen","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115443_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/cells9041001","article-title":"Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs","volume":"9","author":"Sachinidis","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bcp.2023.115443_b0215","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/01.RES.0000033988.13062.7C","article-title":"L-type Ca2+ channel density and regulation are altered in failing human ventricular myocytes and recover after support with mechanical assist devices","volume":"91","author":"Chen","year":"2002","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0220","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/CIRCRESAHA.117.310230","article-title":"Calcium and Excitation-Contraction Coupling in the Heart","volume":"121","author":"Eisner","year":"2017","journal-title":"Circ. Res."},{"issue":"16","key":"10.1016\/j.bcp.2023.115443_b0225","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/0008-5472.CAN-07-6195","article-title":"Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2023.115443_b0230","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/MPA.0b013e31828fd141","article-title":"Modulation of pancreatic tumor potential by overexpression of protein kinase C \u03b21","volume":"42","author":"Cirigliano","year":"2013","journal-title":"Pancreas"},{"issue":"23","key":"10.1016\/j.bcp.2023.115443_b0235","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1158\/0008-5472.CAN-06-2386","article-title":"Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells","volume":"66","author":"Li","year":"2006","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0240","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.bjc.6604566","article-title":"Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells","volume":"99","author":"Tekle","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2023.115443_b0245","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1158\/0008-5472.CAN-08-3187","article-title":"Protein kinase Cbeta is an effective target for chemoprevention of colon cancer","volume":"69","author":"Fields","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2023.115443_b0250","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1535-7163.MCT-07-0547","article-title":"Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells","volume":"7","author":"Morgillo","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2007.00977.x","article-title":"Inhibitors of protein kinase C sensitise multiple myeloma cells to common genotoxic drugs","volume":"80","author":"Baumann","year":"2008","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115443_b0260","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.ejca.2008.03.024","article-title":"Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C","volume":"44","author":"Jasinski","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10637-007-9079-y","article-title":"Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis","volume":"26","author":"Dudek","year":"2008","journal-title":"Invest. New Drugs"},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0270","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdm463","article-title":"A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma","volume":"19","author":"Morschhauser","year":"2008","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2012.07.007","article-title":"A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer","volume":"78","author":"Gr\u00f8nberg","year":"2012","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"12","key":"10.1016\/j.bcp.2023.115443_b0280","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/neuonc\/nor130","article-title":"Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma","volume":"13","author":"Butowski","year":"2011","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2023.115443_b0285","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3109\/10428194.2011.572265","article-title":"Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma","volume":"52","author":"Querfeld","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.bcp.2023.115443_b0290","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3109\/10428194.2013.861066","article-title":"A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma","volume":"55","author":"Jourdan","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/neuonc\/nop042","article-title":"A phase I\/II trial of enzastaurin in patients with recurrent high-grade gliomas","volume":"12","author":"Kreisl","year":"2010","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0300","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/neuonc\/nou114","article-title":"A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study","volume":"17","author":"Kilburn","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2023.115443_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106900","article-title":"Revisiting the hERG safety margin after 20 years of routine hERG screening","volume":"105","author":"Leishman","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"21","key":"10.1016\/j.bcp.2023.115443_b0310","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bcp.2023.115443_b0315","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2217\/fon-2020-0176","article-title":"ENGINE: a Phase III randomized placebo controlled study of enzastaurin\/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1","volume":"16","author":"Nowakowski","year":"2020","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0320","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2023.115443_b0325","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ahj.2007.01.040","article-title":"Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes","volume":"153","author":"Gupta","year":"2007","journal-title":"Am. Heart J."},{"issue":"11","key":"10.1016\/j.bcp.2023.115443_b0330","doi-asserted-by":"crossref","first-page":"10120","DOI":"10.1074\/jbc.M310683200","article-title":"Physicochemical features of the HERG channel drug binding site","volume":"279","author":"Fernandez","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0335","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1161\/CIRCEP.113.000239","article-title":"Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome","volume":"6","author":"Veerman","year":"2013","journal-title":"Circ. Arrhythm. Electrophysiol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0340","first-page":"H1757","article-title":"A rapidly activating delayed rectifier K+ current regulates pacemaker activity in adult mouse sinoatrial node cells","volume":"286","author":"Clark","year":"2004","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"key":"10.1016\/j.bcp.2023.115443_b0345","doi-asserted-by":"crossref","unstructured":"J. Alig, L. Marger, P. Mesirca, H. Ehmke, M.E. Mangoni, D. Isbrandt, Control of heart rate by cAMP sensitivity of HCN channels, Proceedings of the National Academy of Sciences of the United States of America 106(29) (2009) 12189-12194. doi.org\/10.1073\/pnas.0810332106.","DOI":"10.1073\/pnas.0810332106"},{"issue":"2","key":"10.1016\/j.bcp.2023.115443_b0350","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbamcr.2017.11.001","article-title":"Mechanical stretch increases L-type calcium channel stability in cardiomyocytes through a polycystin-1\/AKT-dependent mechanism","volume":"1865","author":"C\u00f3rdova-Casanova","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2023.115443_b0355","article-title":"Role of Reduced Sarco-Endoplasmic Reticulum Ca-ATPase Function on Sarcoplasmic Reticulum Ca Alternans in the Intact Rabbit Heart","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Physiol."},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0360","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/01.RES.0000119923.64774.72","article-title":"Sarcoplasmic reticulum calcium content fluctuation is the key to cardiac alternans","volume":"94","author":"D\u00edaz","year":"2004","journal-title":"Circ. Res."},{"issue":"35","key":"10.1016\/j.bcp.2023.115443_b0365","doi-asserted-by":"crossref","first-page":"13650","DOI":"10.1074\/jbc.RA118.003760","article-title":"The cardiac ryanodine receptor, but not sarcoplasmic reticulum Ca-ATPase, is a major determinant of Ca alternans in intact mouse hearts","volume":"293","author":"Sun","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2023.115443_b0370","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1006\/jmcc.1998.0834","article-title":"Sarcoplasmic reticulum function in murine ventricular myocytes overexpressing SR CaATPase","volume":"30","author":"Yao","year":"1998","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115443_b0375","first-page":"H1146","article-title":"Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activity","volume":"286","author":"Schultz","year":"2004","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"issue":"5","key":"10.1016\/j.bcp.2023.115443_b0380","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.yjmcc.2005.02.017","article-title":"Protein kinase C delta and epsilon mediate positive inotropy in adult ventricular myocytes","volume":"38","author":"Kang","year":"2005","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115443_b0385","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:17:39Z","timestamp":1762096659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223000345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":77,"alternative-id":["S0006295223000345"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115443","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzastaurin cardiotoxicity: QT interval prolongation, negative inotropic responses and negative chronotropic action","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115443"}}